Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney U Anderson

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The Journal of Urology|October 20, 2009
Painful myofascial trigger points and pain sites in men with chronic prostatitis/chronic pelvic pain syndromeRodney U Anderson, Timothy Sawyer, David Wise, et al.
Applied Psychophysiology and Biofeedback|January 2, 2016
Equal Improvement in Men and Women in the Treatment of Urologic Chronic Pelvic Pain Syndrome Using a Multi-modal Protocol with an Internal Myofascial Trigger Point WandRodney U Anderson, David Wise, Tim Sawyer, et al.
The Journal of Urology|January 22, 2008
Psychometric profiles and hypothalamic-pituitary-adrenal axis function in men with chronic prostatitis/chronic pelvic pain syndromeRodney U Anderson, Elaine K Orenberg, Christine A Chan, et al.
The Journal of Urology|September 19, 2009
Stress induced hypothalamus-pituitary-adrenal axis responses and disturbances in psychological profiles in men with chronic prostatitis/chronic pelvic pain syndromeRodney U Anderson, Elaine K Orenberg, Angie Morey, et al.
American Journal of Obstetrics and Gynecology|June 23, 2005
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trialFranklin M Chu, Roger R Dmochowski, Daniel J Lama, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|May 26, 2006
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladderRodney U Anderson, Scott MacDiarmid, Sherron Kell, et al.
Applied Psychophysiology and Biofeedback|February 25, 2015
Chronic pelvic pain syndrome: reduction of medication use after pelvic floor physical therapy with an internal myofascial trigger point wandRodney U Anderson, Richard H Harvey, David Wise, et al.
Archives of Internal Medicine|September 30, 2010
Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trialMichel A Pontari, John N Krieger, Mark S Litwin, et al.
The New England Journal of Medicine|December 19, 2008
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndromeJ Curtis Nickel, John N Krieger, Mary McNaughton-Collins, et al.
The Journal of Urology|June 19, 2009
Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromesMary P FitzGerald, Rodney U Anderson, Jeannette Potts, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The Journal of Urology|October 20, 2009
Painful myofascial trigger points and pain sites in men with chronic prostatitis/chronic pelvic pain syndromeRodney U Anderson, Timothy Sawyer, David Wise, et al.
Applied Psychophysiology and Biofeedback|January 2, 2016
Equal Improvement in Men and Women in the Treatment of Urologic Chronic Pelvic Pain Syndrome Using a Multi-modal Protocol with an Internal Myofascial Trigger Point WandRodney U Anderson, David Wise, Tim Sawyer, et al.
The Journal of Urology|January 22, 2008
Psychometric profiles and hypothalamic-pituitary-adrenal axis function in men with chronic prostatitis/chronic pelvic pain syndromeRodney U Anderson, Elaine K Orenberg, Christine A Chan, et al.
The Journal of Urology|September 19, 2009
Stress induced hypothalamus-pituitary-adrenal axis responses and disturbances in psychological profiles in men with chronic prostatitis/chronic pelvic pain syndromeRodney U Anderson, Elaine K Orenberg, Angie Morey, et al.
American Journal of Obstetrics and Gynecology|June 23, 2005
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trialFranklin M Chu, Roger R Dmochowski, Daniel J Lama, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|May 26, 2006
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladderRodney U Anderson, Scott MacDiarmid, Sherron Kell, et al.
Applied Psychophysiology and Biofeedback|February 25, 2015
Chronic pelvic pain syndrome: reduction of medication use after pelvic floor physical therapy with an internal myofascial trigger point wandRodney U Anderson, Richard H Harvey, David Wise, et al.
Archives of Internal Medicine|September 30, 2010
Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trialMichel A Pontari, John N Krieger, Mark S Litwin, et al.
The New England Journal of Medicine|December 19, 2008
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndromeJ Curtis Nickel, John N Krieger, Mary McNaughton-Collins, et al.
The Journal of Urology|June 19, 2009
Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromesMary P FitzGerald, Rodney U Anderson, Jeannette Potts, et al.
Pageof 3